分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Naringin Interferes Doxorubicin-Induced Myocardial Injury by Promoting the Expression of ECHS1

Zhao Zirui, Yang Shilei, Deng Yawen, Wang Liang, Zhang Yifen, Feng Zhenyu, Li Han, Chi Zhongchao, Xie Yunpeng, Dong Deshi

Journal:Frontiers in Pharmacology

IF:5.99

DOI:10.3389/fphar.2022.859755

PMID:35496302

Published:2022-04-12

research field:

Abstract

Doxorubicin (DOX) leads to myocardial cell damage and irreversible heart failure, which limits the clinical application of DOX. Naringin has biological functions of inhibiting inflammation, oxidative stress and apoptosis. Our aim was to investigate whether Naringin could prevent DOX-related cardiotoxicity in mice. Naringin was administered by gavage and mice were intraperitoneally injected with doxorubicin (1 mg/kg/day) for 15 days. H&E, Masson, TUNEL and others experiments were examined. NRVMs and H9C2 cells were treated with Naringin and DOX in vitro. Using IF, ELISA and Western Blot to detect the effect of Naringin and ECHS1 on cells. The results showed that Naringin could prevent DOX related cardiac injury, inhibit cardiac oxidative stress, inflammation and apoptosis in vivo and in vitro. Inhibition of ECHS1 could interfere the effect of Naringin on DOX-induced myocardial injury. Naringin may provide a new cardiac protective tool for preventing the cardiotoxicity of anthracycline drugs.

本文使用的Yeasen产品

购物车
客服
转染试用